METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Vitamin B3 shows promise in battle against fatty liver disease
Disease control Recruiting nowThis study looks at whether a low dose of vitamin B3 (niacin) can help lower fat buildup in the liver for people with a condition called MASLD (fatty liver disease). The researchers will compare niacin to a placebo in 36 adults aged 50 to 80. The goal is to see if niacin can redi…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: NA • Sponsor: Université de Sherbrooke • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug shows promise for fatty liver disease in early trial
Disease control Recruiting nowThis early-phase study tests whether the drug miricorilant can lower fat production in the liver for people with MASH, a common liver condition linked to metabolism. Eight participants will take the drug for 6 weeks, and researchers will measure changes in liver fat using scans a…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New Gene-Targeting drug for fatty liver disease enters human testing
Disease control Recruiting nowThis study tests an experimental drug called ALN-PNP for metabolic dysfunction-associated steatotic liver disease (MASLD). It is the first time this drug is being tested in humans. The study includes healthy adults and people with MASLD who have a specific gene variant. The main …
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 16:02 UTC